Company: CDLX
Filing Date: 2025-04-03
Form Type: ARS
Source: 0001666071-25-000048
Chunk: 75

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: ARS
Chunk 75
---
 in contingent consideration 210 1,246 (128,174) Foreign currency loss (gain) 1,269 (3,304) 6,376 Impairment of goodwill and intangible assets 131,595 70,518 453,288 Gain on debt extinguishment (13,017) — — Loss on divestiture — 6,550 — Restructuring and reduction of force — — 8,139 Income tax benefit — — (1,446) Adjusted EBITDA $ 2,523 $ 3,771 $ (45,169) Adjusted Net Loss The following table presents a reconciliation of Adjusted Net Loss to Net Loss, the most directly comparable GAAP measure, for each of the periods indicated (in thousands): Year Ended December 31, 2024 2023 2022 Net Loss $ (189,304) $ (134,702) $ (465,264) Plus: Stock-based compensation expense 40,367 40,980 44,686 Foreign currency loss (gain) 1,269 (3,304) 6,376 Acquisition, integration and divestiture costs (benefits) 161 (6,313) (2,874) Amortization of acquired intangibles 9,810 13,589 25,019 Change in contingent consideration 210 1,246 (128,174) Impairment of goodwill and intangible assets 131,595 70,518 453,288 Gain on debt extinguishment (13,017) — — Loss on divestiture — 6,550 — Restructuring and reduction of force — — 8,139 Income tax benefit — — (1,446) Adjusted Net Loss $ (18,909) $ (11,436) $ (60,250) Weighted-average number of shares of common stock used in computing Adjusted net loss per share: Weighted-average common shares outstanding, diluted 48,361 36,488 33,419 Adjusted Net Loss per share, diluted $ (0.39) $ (0.31) $ (1.80) 45

Free Cash Flow The following is a reconciliation of free cash flow to the most comparable GAAP measure, net cash used in operating activities (in thousands): Year Ended December 31, 2024 2023 2022 Net cash used in operating activities $ (8,824) $ (185) $ (53,904